Innoviva Inc. (INVA) exhibits 74.8% gross margins and 14.7% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 7.6x enterprise multiple and 4.8% implied options volatility.
Sustained 74.8% gross profitability converts into 39.8% operating margin and 14.7% ROIC, outpacing sector cost of capital.
ROIC: 14.7% // GM: 74.8%YoY revenue trajectory of +14.7% paired with 12.72% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +14.7% // FCF YLD: 12.72%Altman Z-Score of 3.80 and Piotroski F-Score of 6/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.80 // F-SCORE: 6/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: 7.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $21.31 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend — net margins.
NET MARGIN: — // D/E: 0.22x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for INVA & activate live FRED threshold breach alerts.